AbbVie Sues US Government Over Botox Price Controls
AbbVie sued federal health agencies today to block price controls on Botox. The drugmaker argues the medication is exempt from the Inflation Reduction Act.
Insights:
AbbVie Inc. filed a federal lawsuit on February 11, 2026, in a Washington, D.C. federal court against the U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services. The legal challenge seeks to overturn the imposition of Medicare price controls on Botox, a product that is central to the company’s portfolio. AbbVie is asking the court to end these controls, asserting that the federal government has misapplied the law in its implementation of drug pricing regulations.
